FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Oncology · 12.06.2026 · 1-14
DOI: 10.1159/000552987 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Oncology, online erschienen am 12.06.2026. Verfasst von Mohammed Abdulgayoom und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols, Induction Chemotherapy. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The standard induction regimen for newly diagnosed acute myeloid leukemia (AML) in eligible patients remains cytarabine–daunorubicin (7+3), although FLAG-based regimens are increasingly used in high-risk disease.
Methods
We performed a PRISMA 2020-compliant systematic review and meta-analysis comparing FLAG-based induction with standard 7+3 in adults with newly diagnosed AML. Five retrospective cohort studies, including 534 patients, were analyzed.
Results
FLAG-based induction was associated with a significantly higher overall response rate than 7+3 (OR: 1.83, 95% CI: 1.03–3.22), without a significant difference in 30-day mortality (OR 0.56, 95% CI: 0.12–2.69) or 60-day mortality (OR: 0.79, 95% CI: 0.29–2.14). Survival outcomes were heterogeneous and could not be pooled: median overall survival (OS) was similar in 1 cohort, whereas 2 studies reported improved OS with FLAG-based induction; disease-free survival/relapse-free survival outcomes were inconsistently reported. FLAG-based induction was associated with higher receipt of consolidation therapy, while bridging to allogeneic transplantation did not differ significantly. Cytogenetic and molecular risk data were variably defined and incompletely reported, precluding reliable pooled subgroup analyses.
Conclusions
Overall, FLAG-based induction improves response rates without a clear increase in early mortality or selected reported safety outcomes; however, its impact on survival remains uncertain and appears influenced by post-remission strategies. Prospective randomized trials are needed to better define its role in frontline AML therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar, mmohammed35@hamad.qa.
- Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.
- College of Medicine, Qatar University, Doha, Qatar.
- Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.
- Pharmacy Department, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
Zitieren
APA
Abdulgayoom, M., Aboukhalaf, S., Osman, M., H Soliman, N., Rahmoon, S. M., Rabadi, M., Fituri, N., Al-Mashdali, A. F., Kaddoura, R., & F Mohamed, S. (2026). FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Oncology, 1-14. https://doi.org/10.1159/000552987
Vancouver
Abdulgayoom M, Aboukhalaf S, Osman M, H Soliman N, Rahmoon SM, Rabadi M, et al. FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Oncology. 2026:1-14. doi:10.1159/000552987
BibTeX
@article{Abdulgayoom2026,
author = {Abdulgayoom, Mohammed and Aboukhalaf, Soha and Osman, Mahmoud and H Soliman, Nada and Rahmoon, Samreen Mumtaz and Rabadi, Marrita and Fituri, Nuha and Al-Mashdali, Abdulrahman F and Kaddoura, Rasha and F Mohamed, Shehab},
title = {FLAG-Based versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis},
journal = {Oncology},
year = {2026},
pages = {1--14},
doi = {10.1159/000552987}
}
EUVIMED